Modulation of Immunologic Response by Preventive Everolimus Application in a Rat CPB Model
暂无分享,去创建一个
A. Lichtenberg | P. Akhyari | U. Boeken | A. Jahn | M. Immohr | A. Jenke | Antonio Pinto | M. Kornfeld | Laura Döhrn
[1] J. Kellum,et al. Acute kidney injury in severe sepsis: pathophysiology, diagnosis, and treatment recommendations. , 2015, Journal of veterinary emergency and critical care.
[2] G. Vilahur,et al. Ischemia/reperfusion activates myocardial innate immune response: the key role of the toll-like receptor , 2014, Front. Physiol..
[3] G. Junge,et al. The role of everolimus in liver transplantation , 2014, Clinical and experimental gastroenterology.
[4] A. Lichtenberg,et al. A cardiopulmonary bypass with deep hypothermic circulatory arrest rat model for the investigation of the systemic inflammation response and induced organ damage , 2014, Journal of Inflammation.
[5] M. White,et al. Effect of everolimus on the immunomodulation of the human neutrophil inflammatory response and activation , 2014, Cellular and Molecular Immunology.
[6] G. Semenza,et al. Hypoxia-inducible factor 1 is required for remote ischemic preconditioning of the heart , 2013, Proceedings of the National Academy of Sciences.
[7] R. Hall. Identification of inflammatory mediators and their modulation by strategies for the management of the systemic inflammatory response during cardiac surgery. , 2013, Journal of cardiothoracic and vascular anesthesia.
[8] J. Dieleman. Corticosteroids for the inflammatory response to cardiopulmonary bypass: an update. , 2013, Current pharmaceutical design.
[9] J. Mathew,et al. Degree of hypothermia in aortic arch surgery - optimal temperature for cerebral and spinal protection: deep hypothermia remains the gold standard in the absence of randomized data. , 2013, Annals of cardiothoracic surgery.
[10] Y. V. Bayrakova,et al. Perioperative Dynamics of TLR2, TLR4, and TREM-1 Expression in Monocyte Subpopulations in the Setting of On-Pump Coronary Artery Bypass Surgery , 2013, ISRN inflammation.
[11] C. Ensor,et al. Proliferation signal inhibitor toxicities after thoracic transplantation , 2013, Expert opinion on drug metabolism & toxicology.
[12] B. Nashan,et al. Wound Healing Complications and the Use of Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation: A Critical Review of the Literature , 2012, Transplantation.
[13] D. Schrijvers,et al. Everolimus Triggers Cytokine Release by Macrophages: Rationale for Stents Eluting Everolimus and a Glucocorticoid , 2012, Arteriosclerosis, thrombosis, and vascular biology.
[14] G. Pasterkamp,et al. The innate immune response in reperfused myocardium. , 2012, Cardiovascular research.
[15] E. Chuluyan,et al. Preconditioning donor with a combination of tacrolimus and rapamacyn to decrease ischaemia–reperfusion injury in a rat syngenic kidney transplantation model , 2012, Clinical and experimental immunology.
[16] A. Yoshimura,et al. IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis. , 2011, International immunology.
[17] O. McCarty,et al. S6K1 and mTOR regulate Rac1-driven platelet activation and aggregation. , 2011, Blood.
[18] V. Chopra,et al. Plasma interleukin-10 levels and adverse outcomes in acute coronary syndrome. , 2011, The American journal of medicine.
[19] E. D. de Vries,et al. Everolimus induces rapid plasma glucose normalization in insulinoma patients by effects on tumor as well as normal tissues. , 2011, The oncologist.
[20] R. Hirose,et al. Donor pre-treatment with everolimus or cyclosporine does not reduce ischaemia-reperfusion injury in a rat kidney transplant model. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[21] H. Ross,et al. Everolimus: efficacy and safety in cardiac transplantation , 2010, Expert opinion on drug safety.
[22] D. Granger,et al. Role of blood cells in ischaemia-reperfusion induced endothelial barrier failure. , 2010, Cardiovascular research.
[23] C. Weber,et al. Chemokine CCL5/RANTES inhibition reduces myocardial reperfusion injury in atherosclerotic mice. , 2010, Journal of molecular and cellular cardiology.
[24] M. Gaestel,et al. Cross-regulation of cytokine signalling: pro-inflammatory cytokines restrict IL-6 signalling through receptor internalisation and degradation , 2010, Journal of Cell Science.
[25] A. Fernández,et al. Preoperative statin treatment reduces systemic inflammatory response and myocardial damage in cardiac surgery. , 2009, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[26] S. Sindel,et al. Effects of Everolimus on Cytokines, Oxidative Stress, and Renal Histology in Ischemia-Reperfusion Injury of the Kidney , 2009, Renal failure.
[27] A. Thomson,et al. Immunoregulatory functions of mTOR inhibition , 2009, Nature Reviews Immunology.
[28] F. Schmitz,et al. Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells , 2008, European journal of immunology.
[29] A. Corsini,et al. Fluvastatin Synergistically Improves the Antiproliferative Effect of Everolimus on Rat Smooth Muscle Cells by Altering p27Kip1/Cyclin E Expression , 2008, Molecular Pharmacology.
[30] D. Teupser,et al. Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR-/- mice despite severe hypercholesterolemia. , 2008, Atherosclerosis.
[31] Suzanne F. Jones,et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] R. Negrin,et al. Interleukin-2 receptor downstream events in regulatory T cells: Implications for the choice of immunosuppressive drug therapy , 2008, Cell cycle.
[33] Sang Won Suh,et al. Hypoglycemic neuronal death is triggered by glucose reperfusion and activation of neuronal NADPH oxidase. , 2007, The Journal of clinical investigation.
[34] H. Gruber,et al. Combined enzymatic and antioxidative treatment reduces ischemia-reperfusion injury in rabbit skeletal muscle. , 2006, The Journal of surgical research.
[35] G. Dreyfus,et al. Modulation of Systemic Inflammatory Response after Cardiac Surgery , 2005, Asian cardiovascular & thoracic annals.
[36] Yuval Dor,et al. Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. , 2005, Genes & development.
[37] D. Guertin,et al. Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.
[38] C. Ponticelli,et al. The pleiotropic effects of mTor inhibitors. , 2004, Journal of nephrology.
[39] M. Castresana,et al. Rapamycin inhibits release of tumor necrosis factor-alpha from human vascular smooth muscle cells. , 2004, The American surgeon.
[40] Sarah L. Gaffen,et al. The Interleukin (IL)‐2 Family Cytokines: Survival and Proliferation Signaling Pathways in T Lymphocytes , 2004, Immunological investigations.
[41] C. Collard,et al. The systemic inflammatory response to cardiopulmonary bypass. , 2003, Anesthesiology clinics of North America.
[42] R. Virmani,et al. Oral Everolimus Inhibits In-Stent Neointimal Growth , 2002, Circulation.
[43] Schmucker,et al. Perioperative serum levels of tumour‐necrosis‐factor alpha (TNF‐α), IL‐1β, IL‐6, IL‐10 and soluble IL‐2 receptor in patients undergoing cardiac surgery with cardiopulmonary bypass without and with correction for haemodilution , 1999, Clinical and experimental immunology.
[44] K. Nadeau,et al. The cytokine-adhesion molecule cascade in ischemia/reperfusion injury of the rat kidney. Inhibition by a soluble P-selectin ligand. , 1997, The Journal of clinical investigation.
[45] B. Ryffel,et al. Effect of rapamycin on the expression of the IL‐2 receptor (CD25) , 1996, Clinical and experimental immunology.
[46] M. Janier,et al. Rate of glycolysis during ischemia determines extent of ischemic injury and functional recovery after reperfusion. , 1994, The American journal of physiology.
[47] F. Mohr,et al. Modern temperature management in aortic arch surgery: the dilemma of moderate hypothermia. , 2014, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[48] D. Fingar,et al. Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. , 2012, The Biochemical journal.
[49] K. Lehle,et al. Predominant inhibition of interleukin-6 synthesis in patient-specific endothelial cells by mTOR inhibitors below a concentration range where cell proliferation is affected and mitotic arrest takes place. , 2005, Transplantation proceedings.
[50] M. Manns,et al. Clinical Pharmacokinetics of Everolimus , 2004, Clinical pharmacokinetics.
[51] D. Fairlie,et al. Protective effects of a potent C5a receptor antagonist on experimental acute limb ischemia-reperfusion in rats. , 2004, The Journal of surgical research.
[52] G. Lopaschuk,et al. An imbalance between glycolysis and glucose oxidation is a possible explanation for the detrimental effects of high levels of fatty acids during aerobic reperfusion of ischemic hearts. , 1993, The Journal of pharmacology and experimental therapeutics.